Prognostic factors in dogs with presumed degenerative mitral valve disease attending primary care veterinary practices in the UK
(2018)
Journal Article
Mattin, M. J., Boswood, A., Church, D. B., & Brodbelt, D. C. (2018). Prognostic factors in dogs with presumed degenerative mitral valve disease attending primary care veterinary practices in the UK. Journal of Veterinary Internal Medicine, 33(2), 432-444. https://doi.org/10.1111/jvim.15251
All Outputs (3)
Serum cardiac troponin I concentrations in dogs with generalised seizures (2018)
Journal Article
Dutton, E., Carmichael, N., Michal, U., Cripps, P. J., & Boswood, A. (2018). Serum cardiac troponin I concentrations in dogs with generalised seizures. Journal of Small Animal Practice, 59(3), 167-173. https://doi.org/10.1111/jsap.12771
Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study (2018)
Journal Article
Boswood, A., Gordon, S. G., Häggström, J., Wess, G., Stepien, R. L., Oyama, M. A., Keene, B. W., Bonagura, J. D., MacDonald, K. A., Patteson, M., Smith, S., Fox, P. R., Sanderson, K., Woolley, R., Szatmári, V., Menaut, P., Church, W. M., O'Sullivan, M. L., Jaudon, J. P., Kresken, J.-G., …Watson, P. (2018). Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study. Journal of Veterinary Internal Medicine, 32(1), 72-85. https://doi.org/10.1111/jvim.14885Background: Changes in clinical variables associated with the administration of pimobendan to dogs with preclinical myxomatous mitral valve disease (MMVD) and cardiomegaly have not been described.
Objectives: To investigate the effect of pimobenda... Read More about Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.